2.1. MYC Downregulation by Synthetic MYC Inhibitor 10058-F4 Sensitizes Lymphoma Cells Towards Rituximab-Mediated Antibody-Dependent Cellular Cytotoxicity Through CD20 Upregulation. The gene discussed is MS4A1; the disease is lymphoma.